IngredientsGrapefruit (Citrus × paradisi) is a citrus tree of the family Rutaceae and its edible fruit. Grapefruit is a natural hybrid of sweet orange and pomelo. It is an important citrus commodity that originated in Barbados in the 17th century and is the youngest member of the genus Citrus. The accepted scientific binomial is Citrus × paradisi Macfad., with the synonym Citrus × aurantium also appearing in formal botanical literature. Grapefruit belongs to the Sapindales order and the Rutaceae family, alongside fruits like oranges, lemons, and limes. Botanically, grapefruits and other citrus fruits are a type of berry known as a hesperidium.
Most commercially important grapefruit cultivars arose through natural and induced mutations, not traditional breeding, of the white-fleshed and seedy Duncan grapefruit. Cultivars with a range of flesh colors now exist, and the pigmentation is correlated with lycopene content. Cultivars include white/yellow-fleshed types and pigmented pink and red types, with the latter having higher lycopene concentrations.
Parts used include the fruit, peel, essential oil from the peel, and seeds (extract). Commercial preparations derived from grapefruit include:
Grapefruit originated in Barbados in the 17th century, evolving into a major agricultural commodity. The grapefruit probably originated in Barbados as a hybrid of shaddock (Citrus grandis). It became well established as a fruit for home consumption in the islands of the West Indies before its culture spread to the American mainland.
Grapefruit has become popular as a breakfast fruit in various parts of the world, and production has expanded to most citrus-growing countries, notably the United States, Israel, Cyprus, South Africa, and Brazil. In the Western world, grapefruits were introduced in the 18th century and quickly became a popular fruit among the aristocracy. They were often served as a dessert or used in marmalades and preserves.
While not extensively documented in formal traditional medicine systems like Traditional Chinese Medicine or Ayurveda, grapefruit juice has been recognized in various cultures for its potential health benefits. It has been used as a folk remedy for colds and flu due to its high vitamin C content. Some traditional practices involve using grapefruit juice as a digestive aid, with the belief that its acidity can stimulate digestion.
Grapefruit has been part of many diets since its incorporation into the "Hollywood" diet of hard-boiled eggs, green vegetables, and "melba" toast in 1930 as an anti-obesity ingredient. It has also been incorporated into some weight loss diets due to its low calorie and high fiber content, although scientific evidence for its efficacy in weight loss is limited. The primary historical usage of grapefruit juice is as a refreshing and palatable beverage rather than a formal medicinal treatment.
In Ayurvedic herbalism, Citrus paradisi stands out for its unique blend of pungent and bitter tastes, cooling energy, and capacity to balance Kapha and Pitta doshas. It should be noted that grapefruit, as a relatively young species originating in the 17th century, does not have an extensive formal history in classical herbal traditions such as Traditional Chinese Medicine or Ayurveda, which predate its existence; references to it in such contexts reflect modern adaptations rather than ancient classical texts.
Naringin (4′,5,7-trihydroxyflavanone-7-rhamnoglucoside) and its aglycone form naringenin belong to the flavonoid class known as flavanones and are found mainly in citrus fruits, including lemon, orange, mandarin, and grapefruit. Naringin and naringenin, which belong to a subclass of flavonoids known as flavanones, are the main bioactive compounds in citrus fruits, and they are known for their beneficial effects on human health. Other flavanones detected in grapefruit juice include narirutin, hesperidin, neohesperidin, didymin, and poncirin.
When the highly lipophilic naringin is given orally, it is converted to its absorbable form naringenin and is hydrolyzed by intestinal microflora. After single ingestions of grapefruit juice (8 mL/kg) in healthy volunteers, the mean peak plasma concentration (Cmax) of naringenin was 0.7–14.8 μM.
Furanocoumarins are a specific group of secondary metabolites that commonly present in higher plants such as citrus plants. The major furanocoumarins found in grapefruits (Citrus paradisi) include bergamottin, epoxybergamottin, and 6′,7′-dihydroxybergamottin. Furanocoumarins related to bergamottin are primarily responsible for the grapefruit–drug interaction effect, yet the exact mechanisms and roles that specific compounds play in this effect are still uncertain. Bergamottin is a furanocoumarin derived from grapefruits and is also a well-known cytochrome P450 inhibitor.
The peel is constituted by a large number of compounds that can be classified in 7 main groups: terpenes, sesquiterpene hydrocarbons, alcohols, aldehydes, esters, oxides, and a variety of other compounds. Terpenes are the most prevalent compounds, with limonene, myrcene, citral, and terpine constituting about 80% of the peel. Nootkatone, α- and β-sinensal, methyl-N-methylanthranilate, and (Z,E)-farnesol are prominent constituents of grapefruit essential oil.
Cultivars with a range of flesh colors exist, and the pigmentation is correlated with lycopene content. Red and pink varieties contain significant lycopene, the carotenoid pigment that has attracted research interest for its antioxidant properties. Red and pink grapefruit are good sources of beta-carotene and lycopene, which may reduce inflammation and the risk of chronic diseases.
As a source of vitamin C, the grapefruit is exceeded among common fruits only by the orange and lemon. Grapefruit is an excellent source of vitamin C, providing 64% of the daily value in just half a grapefruit. It is also a good source of vitamin A, fiber, and potassium.
Grapefruit seeds have a high essential oil content reaching 36.5%, as well as 13.5% humidity, 8.5% fiber, and 4.1% consisting of a complex mixture of lipids, alcohols, fatty acids, tocopherol, flavonoids, polyphenols and aglycone limonoids. Limonin is a limonoid found in grapefruit juice in amounts detectable by HPLC and is present at higher levels in juice produced by blending.
The chemicals in grapefruit involved in drug interactions are the furanocoumarins. Furanocoumarins are metabolized by CYP3A4 to reactive intermediates that bond covalently to the active site of the enzyme, causing irreversible inactivation (mechanism-based inhibition). Consequently, CYP3A4 activity in the small intestine is impaired until de novo synthesis returns the enzyme to its previous level.
The effects are caused by furanocoumarins (and, to a lesser extent, flavonoids), which inhibit key drug-metabolizing enzymes such as cytochrome P450 3A4 (CYP3A4). CYP3A4 is a metabolizing enzyme for almost 50% of drugs, and is found in the liver and small intestinal epithelial cells.
Naringin was identified as a major and selective clinical inhibitor of organic anion transporter polypeptide 1A2 (OATP1A2) in grapefruit juice. This flavonoid has the opposite effect of furanocoumarins, helping to reduce drug absorption — particularly of fexofenadine — via grapefruit juice's inhibition of the activity of an OATP family protein transporter. Thus, grapefruit has a dual and sometimes opposing effect on oral drug bioavailability depending on whether the affected drug is a CYP3A4 substrate (bioavailability raised) or an OATP substrate (bioavailability reduced).
The grapefruit flavonoid naringenin has been shown to normalize lipids in diabetes and hypercholesterolemia, as well as inhibit the production of HCV. It regulates the activity of nuclear receptors PPARα, PPARγ, and LXRα, activating the ligand-binding domain of both PPARα and PPARγ, while inhibiting LXRα. The flavonoid activates the PPAR response element (PPRE) while suppressing LXRα response element (LXRE) in human hepatocytes, translating into the induction of PPAR-regulated fatty acid oxidation genes such as CYP4A11, ACOX, UCP1, and ApoAI, and inhibition of LXRα-regulated lipogenesis genes such as FAS, ABCA1, ABCG1, and HMGR.
Naringenin (NGN) and naringin (NAR) promote the scavenging of reactive oxygen species (ROS) and free radicals generated from NADPH oxidase and the respiratory activity of the mitochondria. They also inhibit inflammatory cytokine action and attenuate inflammation via the inhibition of NF-κB and regulation of leukocyte adhesion.
In various studies, flavonoids were found capable of demonstrating strong anticancer effects by acting as antioxidants; modulating ROS-scavenging enzyme activity; upregulating apoptosis, autophagy, and cell cycle arrest; and downregulating inflammation, proliferation processes, and metastasis formation.
NGN and NAR protect against the onset and severity of many human diseases via their antioxidant and anti-inflammatory activities, inhibition of adhesion molecules, and enhancement of vascular smooth muscle relaxation in the endothelial cells.
The idea that grapefruit promotes weight loss is longstanding in popular culture, but the clinical evidence is weak and inconsistent.
A systematic review and meta-analysis (Onakpoya et al., 2015) sought to evaluate the evidence for or against the effectiveness of grapefruits on body weight, blood pressure, and lipid profile. Electronic searches were conducted in MEDLINE, EMBASE, AMED, and the Cochrane Clinical Trials databases to identify relevant human randomized clinical trials (RCTs). Only overweight and obese subjects were included. The reporting quality was assessed using the CONSORT checklist and GRADE criteria. One hundred and fifty-four citations were identified and three RCTs with a total of 250 participants were included. The RCTs were of moderate quality. A meta-analysis for change in body weight failed to reveal a significant difference between grapefruits and controls (MD: −0.45 kg; 95% CI: −1.06 to 0.16; I² = 53%).
In one individual RCT, overweight adults (N = 74) following a 3-week washout diet low in bioactive-rich fruits and vegetables were randomized to either the control diet (n = 32) or daily grapefruit (n = 42) in the amount of one half of a fresh Rio-Red grapefruit with each meal (3× daily) for 6 weeks. No significant differences between groups in weight, blood pressure, or lipids were demonstrated between conditions. Within the grapefruit group, consumption was associated with modest weight loss (−0.61 ± 2.23 kg, P = .097) and a significant reduction in waist circumference (−2.45 ± 0.60 cm, P = .0002).
Evidence strength: Current evidence from a small number of moderate-quality RCTs does not demonstrate a statistically significant effect of grapefruit on body weight compared to a control condition. Intra-group improvements in waist circumference have been observed but may not exceed placebo effects.
The meta-analysis by Onakpoya et al. revealed a significant decrease in systolic blood pressure (MD: −2.43 mmHg; 95% CI: −4.77 to approximately −0.09). A randomized controlled trial involving overweight adults found that consuming half a fresh Rio-Red grapefruit with each meal for six weeks led to a significant reduction in systolic blood pressure by 3.21 mmHg compared to baseline values.
Regarding lipids, in the same 6-week RCT, improvements were observed in circulating lipids of those consuming grapefruit, with total cholesterol and low-density lipoprotein significantly decreasing by −11.7 mg/dL (P = .002) and −18.7 mg/dL (P < .001), respectively, compared with baseline values. However, this study suggests that consumption of grapefruit daily for 6 weeks does not significantly decrease body weight, lipids, or blood pressure as compared with the control condition. The improvements in blood pressure and lipids demonstrated in the intervention group suggest that grapefruit should be further evaluated in the context of obesity and cardiovascular disease prevention.
Regarding naringin supplementation and cholesterol, one clinical study demonstrated that administration of naringin (400 mg/capsule/day) with regular meals for 8 weeks lowered plasma total cholesterol by 14% and LDL cholesterol by 17% in hypercholesterolemic subjects.
Evidence strength: Modest and statistically significant reductions in systolic blood pressure have been observed across multiple clinical trials. Effects on lipids are numerically meaningful within-group but have not been consistently demonstrated versus control. Evidence remains preliminary (few small RCTs); larger controlled trials are needed.
A study by Fujioka et al. reported that consumption of whole grapefruit or grapefruit juice is associated with significant weight loss and improved insulin resistance in patients with the metabolic syndrome, compared to placebo. Grapefruit consumption has been associated with decreased fasting blood glucose and insulin levels, and serum total cholesterol, low-density lipoprotein, and triglyceride levels.
Mechanistically, naringenin, a natural flavanone, has been revealed to have pharmacological effects in the treatment of obesity and associated metabolic disorders such as nonalcoholic fatty liver disease (NAFLD). Further careful human pharmacokinetic studies are needed to establish dosage ranges, as well as addressing preliminary safety and tolerability of naringenin, before proceeding to larger-scale endpoint trials. Research is needed to confirm the potential therapeutic effects of naringenin by conducting clinical trials.
For lycopene (the carotenoid concentrated in red/pink grapefruit), lycopene consumption beneficially contributes to protecting against type 2 diabetes in animal studies. However, epidemiological observations and large-scale population studies using human models have revealed a mixed association between lycopene intake and type 2 diabetes.
Evidence strength: Preliminary; most mechanistic data come from animal or in vitro models. Human clinical trial evidence for grapefruit specifically in metabolic syndrome is limited to a small number of studies. The role of isolated naringenin or lycopene in human glycemic control requires larger, rigorous RCTs.
Grapefruit seed extract (GSE) is widely marketed as a natural broad-spectrum antimicrobial; however, the scientific evidence presents significant complications regarding product purity and the source of any observed antimicrobial activity.
Examinations of six commercially available grapefruit seed extracts showed that five of the six extracts demonstrated high growth-inhibiting activity against test germs including Bacillus subtilis, Staphylococcus aureus, Escherichia coli, and Candida maltosa. In all antimicrobial-active grapefruit seed extracts, the preservative benzethonium chloride was detected by thin layer chromatography. Additionally, three extracts contained the preserving substances triclosan and methyl parabene. In the one extract in which no preservative agent was found, as well as in several self-made extracts from seed and juiceless pulp, no antimicrobial activity could be detected. The conclusion reached was that the potent and nearly universal antimicrobial activity attributed to grapefruit seed extract is merely due to the synthetic preservative agents contained within; natural products with antimicrobial activity do not appear to be present.
Evidence strength: The antimicrobial properties commonly attributed to commercial GSE products appear to be due to synthetic adulterants (benzethonium chloride, triclosan), not to intrinsic grapefruit phytochemicals. The evidence base for genuine grapefruit-derived antimicrobial activity in clinical settings is absent.
Citrus paradisi is known to have a variety of phytonutrients, a characteristic that has stimulated investigations to determine its biological and biomedical activities. Dietary intake of flavonoids present in citrus fruits has been associated with a reduced risk of endothelium dysfunction. Naringenin and naringin, major flavonoids in grapefruit, possess anti-inflammatory and antioxidant properties, and cell survival potential, which improve the health of the vascular endothelium.
Evidence strength: Antioxidant and anti-inflammatory mechanisms are well characterized in cell and animal models. Direct human clinical evidence for anti-inflammatory endpoints is sparse and indirect (e.g., through lipid or blood pressure markers). Robust interventional human studies targeting inflammatory biomarkers specifically with grapefruit are lacking.
Naringin and its aglycone naringenin are abundantly present in citrus fruits such as grapefruits. Their anti-carcinogenic activities have been shown to be exerted through several cell signal transduction pathways. Recent studies have demonstrated potent anti-oxidative, anti-inflammatory, and anti-cancer properties of grapefruit furanocoumarin (bergamottin) both in vitro and in vivo.
Evidence strength: Anticancer evidence for grapefruit constituents is predominantly preclinical (in vitro and animal models). No human clinical trials have established grapefruit consumption or its isolated compounds as treatments for cancer in humans. This area of research is exploratory.
The following dosages are reported as stated in the cited sources and do not constitute recommendations.
The FDA recognizes grapefruit juice as a strong inhibitor of cytochrome P450-3A (CYP3A), but also indicates that this reaction may vary depending on dose and concentration. Grapefruit and grapefruit juice are responsible for clinically significant drug interactions due to the inhibition of CYP3A4 in the small intestine.
The US Food and Drug Administration classifies grapefruit as a moderate to strong inhibitor of CYP3A4, which metabolizes approximately 50% of marketed drugs. Researchers have identified over 85 drugs with which grapefruit reacts adversely.
The interaction is greatest when the juice is ingested with the drug or up to four hours before the drug. The location of the inhibition occurs in the lining of the intestines, not within the liver.
There is extensive literature on the interactions between grapefruit juice and various drugs, including anti-cancer agents, anti-infectives, anti-lipemic agents, cardiovascular agents, CNS agents, gastrointestinal and urinary tract agents.
Drug classes with documented or predicted CYP3A4-based interactions include:
Naringin, via grapefruit juice's inhibition of the activity of an OATP family protein transporter, helps to reduce drug absorption — particularly of fexofenadine. The balance between the inverse actions of furanocoumarins (raising bioavailability via CYP3A4 inhibition) and flavonoids (reducing bioavailability via OATP inhibition) makes it difficult to anticipate the bioavailability of drugs when consuming grapefruit juice.
For medications that interact due to inhibition of OATP (organic anion-transporting polypeptides), a relatively short period of time is needed to avoid this interaction, and a four-hour interval between grapefruit consumption and the medication should suffice. In contrast, because CYP3A4 inhibition by furanocoumarins is irreversible (mechanism-based), recovery requires de novo enzyme synthesis and the effect can persist for 24 hours or longer after consumption.
Determining whether the grapefruit juice–drug interaction is clinically significant depends on the extent of the systemic drug concentration and drug toxicity related to the drug concentration. Additionally, several other factors affect it, such as the oral bioavailability of the affected drug, the type of grapefruit or other fruits consumed, and the inter-individual variations in their responses to the interaction.
The effect of grapefruit juice varies widely among brands and is concentration-, dose-, and preparation-dependent.
Exposure to furanocoumarins in large doses combined with ultraviolet radiation, such as through photochemotherapy, is known to induce skin tumorigenesis in both animals and humans. Furanocoumarins are relatively non-volatile molecules and are generally found in expressed (cold-pressed) citrus fruit oils, but not in distilled citrus fruit oils. Thus, topical application of cold-pressed grapefruit peel oil followed by UV exposure carries a documented phototoxicity risk; distilled or furanocoumarin-free preparations do not carry the same risk.
In all antimicrobially active commercial grapefruit seed extracts examined in one peer-reviewed study, the preservative benzethonium chloride was detected by thin layer chromatography; additionally, three extracts contained the preserving substances triclosan and methyl parabene. These synthetic additives represent a safety concern distinct from the inherent phytochemistry of grapefruit, and their presence confounds the assessment of any therapeutic benefit or risk attributed to "natural" GSE.
Numerous studies have confirmed that naringin and naringenin are relatively safe and non-toxic. Further careful human pharmacokinetic studies are needed to establish dosage ranges, as well as addressing preliminary safety and tolerability of naringenin, before proceeding to larger-scale endpoint trials.
Health conditions that Grapefruit may help support.
Grapefruit contains multiple antioxidant compounds including vitamin C, naringenin, naringin, beta-carotene, and lycopene (red variety). Clinical trials confirm that grapefruit consumption significantly increases serum antioxidant activity and reduces urinary F2-isoprostanes, a validated oxidative stress biomarker. The antioxidant properties of naringenin have been extensively characterized in cell culture and animal studies.
Clinical trials suggest grapefruit may reduce appetite and promote satiety when consumed before meals, partly through its fiber content and low energy density. A 12-week Scripps Clinic RCT found that participants eating grapefruit lost weight and showed reduced insulin levels without other dietary changes. Pre-meal grapefruit preloads have been studied as a low-energy-density satiety strategy in obese adults.
Grapefruit contains naringin, naringenin, and lycopene with arterial-relevant activities including HMG-CoA reductase inhibition, reduced LDL oxidation, and anti-inflammatory endothelial effects. Human dietary studies show grapefruit consumption reduces LDL-C by 15–20% in hypercholesterolemic subjects. Grapefruit flavanones also inhibit platelet aggregation.
A meta-analysis of 3 RCTs found grapefruit consumption significantly reduced systolic blood pressure by approximately 2.4 mmHg in overweight adults. Individual trials have also noted significant systolic blood pressure reductions with daily grapefruit intake. Mechanistically, naringenin promotes nitric oxide production and vasorelaxation in vascular models.
Clinical evidence shows that fresh grapefruit consumption does not adversely affect fasting blood glucose or insulin in healthy adults. In a subset of participants with metabolic syndrome, grapefruit consumption was associated with greater reductions in 2-hour insulin levels. The flavonoid naringenin has been proposed to improve glucose handling via intestinal bacterial hydrolysis to active metabolites.
Multiple clinical trials demonstrate that grapefruit and grapefruit pectin reduce total cholesterol and LDL cholesterol in hyperlipidemic adults. Red grapefruit produces larger reductions than blond. Grapefruit pectin supplementation reduced LDL by 10.8% in a double-blind crossover trial. Mechanistically, naringenin inhibits HMG-CoA reductase and activates hepatic fatty acid oxidation pathways.
Grapefruit contains the flavonoids naringenin and naringin, which have demonstrated anti-inflammatory properties in multiple preclinical models via inhibition of NF-κB and reduction of pro-inflammatory cytokines. Clinical data are more limited; a 6-week grapefruit RCT reduced urinary F2-isoprostanes in high-baseline overweight adults but did not significantly lower hsCRP. Naringenin inhibits UVB-induced skin inflammation in animal models.
Several RCTs have evaluated grapefruit for weight management, with modest but inconsistent results. A meta-analysis of 3 RCTs in overweight/obese adults found no significant reduction in body weight but a significant decrease in systolic blood pressure. Individual trials have noted significant reductions in waist circumference with regular grapefruit consumption.
Multiple human studies have found that regular grapefruit consumption reduces LDL cholesterol, total cholesterol, and triglycerides in hyperlipidemic and overweight adults. Observational data link grapefruit consumption to reduced coronary heart disease mortality risk in women. The flavonoids naringenin and naringin have demonstrated antihypertensive and anti-atherosclerotic properties in clinical and preclinical research.
Grapefruit's flavonoid naringenin has been shown to reduce insulin resistance in animal and early human studies, including an 18% reduction in fasting insulin in one clinical trial. Subgroup analyses of RCTs in metabolic syndrome patients show greater 2-hour insulin reductions with grapefruit versus placebo. The mechanism involves PPAR-α/γ activation and AMP kinase signaling.
Grapefruit's flavonoids naringenin and naringin have documented protective effects on the liver, including reduction of fat accumulation, oxidative stress, and inflammatory signaling in NAFLD models. Grapefruit juice inhibits hepatic CYP450 enzymes, modulating phase I liver detoxification. Clinical trial protocols for naringenin in NAFLD have been published, though completed human RCTs are limited.
Grapefruit and its flavonoids (naringin, naringenin) address multiple components of metabolic syndrome simultaneously, including elevated blood pressure, dyslipidemia, abdominal obesity, and insulin resistance. RCT subgroup analyses and epidemiological data specifically in metabolic syndrome patients show greater benefits than in the general population. Naringin supplementation is cited in multiple reviews as beneficial for metabolic syndrome management.
Grapefruit is a rich source of vitamin C, which is essential for collagen synthesis and is established to protect against UV-induced skin damage and support skin hydration. Grapefruit also contains alpha-hydroxy acids (citric, malic, tartaric acid) used in topical skincare for texture and elasticity. Evidence for whole grapefruit consumption directly reducing wrinkles in humans is indirect, mediated through known vitamin C mechanisms.
Red grapefruit has demonstrated significant triglyceride-lowering effects in a controlled human trial of hyperlipidemic coronary patients. NHANES data show grapefruit consumers have significantly lower triglycerides than non-consumers. The effect appears stronger for red versus blond grapefruit and may involve antioxidants and currently unidentified bioactive compounds.
Body systems that Grapefruit may help support.
Go back